-
公开(公告)号：US08846094B2
公开(公告)日：2014-09-30
申请号：US11828561
申请日：2007-07-26
IPC分类号： A61K9/14 , A61K31/56 , A61K47/02 , A61K47/36 , A61K47/40 , A61K31/715 , A61K47/34 , A61K31/573 , A61K9/00
CPC分类号： A61K9/0019 , A61K9/0048 , A61K31/56 , A61K31/573 , A61K31/58 , A61K31/715 , A61K47/02 , A61K47/34 , A61K47/36 , A61K47/40
摘要： Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.
摘要翻译： 提供使用这种组合物的粘性制剂和方法，其可用于肌肉内和关节内注射以治疗外周病症。 这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约80,000cps至约300,000cps的范围内。 在最优选的实施方案中，粘度在25℃下以0.1 /秒的剪切速率在约140,000cps至约280,000cps的范围内。组合物有利地将曲安奈德颗粒悬浮较长时间。
-
公开(公告)号：US20070298074A1
公开(公告)日：2007-12-27
申请号：US11491353
申请日：2006-07-21
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61K31/498 , A61K31/573 , A61K31/58 , A61K47/34
摘要： Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.
-
23.发明申请Steroid-containing sustained release intraocular implants and related methods 审中-公开类固醇持续释放眼内植入物及相关方法公开(公告)号：US20070298073A1
公开(公告)日：2007-12-27
申请号：US11473947
申请日：2006-06-23
IPC分类号： A61F2/02
CPC分类号： A61K9/0051 , A61F9/0017 , A61K9/0092 , A61K9/1641
摘要： Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.
摘要翻译： 生物相容性眼内植入物系统被配制用于治疗剂量（例如类固醇）的不连续或间歇释放以最小化与这种药剂的连续或长期使用相关的副作用的发展。 植入系统可以包括一个或多个植入物，并且优选但不一定也包含具有有效减少与所述治疗剂相关联的至少一种副作用的活性的辅助剂，与使用其它相同的植入物系统相比，缺少所述 辅助剂。 包含治疗剂和辅助剂的植入物可以放置在眼睛中以治疗一种或多种眼部病症，同时减少否则伴随使用这种治疗剂的眼部副作用。
-
24.发明授权公开(公告)号：US08802128B2
公开(公告)日：2014-08-12
申请号：US11491353
申请日：2006-07-21
IPC分类号： A61F2/02 , A61K31/54 , A61K31/56 , A61K31/58 , A61K31/573 , A61K31/575 , A61K31/137 , A61K31/4164 , A61K31/4168 , A61K9/00
CPC分类号： A61K9/0051 , A61K31/498 , A61K31/573 , A61K31/58 , A61K47/34
摘要： Biocompatible intraocular implant systems are formulated for discontinuous or intermittent release of therapeutic levels of a therapeutic agent (such as a steroid) to minimize development of side effects associated with continuous or long term use of such agent. The implant system may comprise one or more implant, and preferably, although not necessarily, also contains an auxiliary agent having an activity effective to lessen at least one side effect associated with said therapeutic agent compared to the use of an otherwise identical implant system lacking said auxiliary agent. The implants containing the therapeutic agent and auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the ocular side effects otherwise accompanying the use of such therapeutic agent.
摘要翻译： 生物相容性眼内植入物系统被配制用于治疗剂量（例如类固醇）的不连续或间歇释放以最小化与这种药剂的连续或长期使用相关的副作用的发展。 植入系统可以包括一个或多个植入物，并且优选但不一定也包含具有有效减少与所述治疗剂相关联的至少一种副作用的活性的辅助剂，与使用其它相同的植入物系统相比，缺少所述 辅助剂。 包含治疗剂和辅助剂的植入物可以放置在眼睛中以治疗一种或多种眼部病症，同时减少否则伴随使用这种治疗剂的眼部副作用。
-
25.发明授权Methods and compositions for intraocular administration to treat ocular conditions 有权用于眼内给药以治疗眼部病症的方法和组合物公开(公告)号：US08642067B2
公开(公告)日：2014-02-04
申请号：US11695527
申请日：2007-04-02
IPC分类号： A61F2/00
CPC分类号： A61K31/404 , A61K9/0048 , A61K31/33 , A61K31/728 , A61K47/14 , A61K47/36 , A61K2300/00
摘要： Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include TKI component solutions or particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.
摘要翻译： 提供了抗血管生成组合物，以及使用这些组合物的方法，其可用于注射到人眼玻璃体中。 这样的组合物可以包括TKI组分溶液或以治疗有效量存在的颗粒，粘度诱导组分和水性载体组分。 组合物在约25℃下的粘度为0.1 /秒的剪切速率为至少约10cps或约100cps。 在优选的实施方案中，25℃下的粘度在约80,000cps至约300,000cps的范围内。
-
公开(公告)号：US20110092443A1
公开(公告)日：2011-04-21
申请号：US12683811
申请日：2010-01-07
摘要： The present invention is directed to cyclosporine compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth the nail. The composition is also effective in strengthening and growing nails, including fingernails and toenails.
摘要翻译： 本发明涉及环孢素组合物和刺激哺乳动物（包括人）中指甲和角质层生长的方法。 组合物可以局部施用于甲床，指甲基质和角质层，其量可有效增加指甲生长并增厚，加强和平滑指甲。 组合也有效地加强和增长指甲，包括指甲和脚趾甲。
-
公开(公告)号：US20080269181A1
公开(公告)日：2008-10-30
申请号：US12172194
申请日：2008-07-11
CPC分类号： A61K31/58 , A61K9/0048 , A61K31/573 , A61K47/36
摘要： Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.
摘要翻译： 提供了组合物和使用这种组合物的方法，其可用于注射到人或动物眼睛的后段中。 这样的组合物包括以治疗有效量存在的含皮质类固醇成分的颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约140,000cps至约300,000cps的范围内。 组合物有利地将颗粒悬浮长时间。
-
公开(公告)号：US20080241219A1
公开(公告)日：2008-10-02
申请号：US12055232
申请日：2008-03-25
申请人： Scott M. Whitcup , David A. Weber
发明人： Scott M. Whitcup , David A. Weber
CPC分类号： A61K9/0051 , A61F9/0017 , A61K9/0024 , A61K9/1647 , A61K31/165 , A61K31/56 , A61K31/57 , A61K39/3955 , A61K47/34 , C07K16/18 , C07K16/22
摘要： Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site.
-
公开(公告)号：US20080233172A1
公开(公告)日：2008-09-25
申请号：US12055235
申请日：2008-03-25
申请人： Scott M. Whitcup , David A. Weber
发明人： Scott M. Whitcup , David A. Weber
CPC分类号： A61K9/0051 , A61F9/0017 , A61K9/0024 , A61K9/1647 , A61K31/165 , A61K31/56 , A61K31/57 , A61K39/3955 , A61K47/34 , C07K16/18 , C07K16/22
摘要： Methods for treating ocular conditions by inserting an implant comprising an active agent into an ocular site of a patient thereby obtaining an amelioration of a symptom of the ocular condition (i.e. a therapeutic effect) for an extended period of time during which a therapeutic amount or a detectable amount of the active agent is not present at the ocular site.
-
公开(公告)号：US08569272B2
公开(公告)日：2013-10-29
申请号：US12172194
申请日：2008-07-11
CPC分类号： A61K31/58 , A61K9/0048 , A61K31/573 , A61K47/36
摘要： Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.
摘要翻译： 提供了组合物和使用这种组合物的方法，其可用于注射到人或动物眼睛的后段中。 这样的组合物包括以治疗有效量存在的含皮质类固醇成分的颗粒，粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中，粘度在约140,000cps至约300,000cps的范围内。 组合物有利地将颗粒悬浮长时间。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.042 秒)
